Search research articles
Contact Us
Filters
Showing results (71-80 of 116) with videos related to
Page
of 12
Sort By:
Journal of Medicinal Chemistry
|
February 3, 2006
GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential
Nigel Irwin, Finbarr P M O'Harte, Victor A Gault, et al.
Biological Chemistry
|
October 21, 2004
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice
Nigel Irwin, Victor A Gault, Brian D Green, et al.
Journal of Medicinal Chemistry
|
February 18, 2005
Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide
Nigel Irwin, Brian D Green, Victor A Gault, et al.
Cell Biology International
|
February 5, 2004
N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression
Hui-Kang Liu, Brian D Green, Victor A Gault, et al.
Biological Chemistry
|
October 7, 2005
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)
Nigel Irwin, Victor A Gault, Brian D Green, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 2, 2006
Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice
Brian D Green, Kerry S Lavery, Nigel Irwin, et al.
Diabetes/Metabolism Research and Reviews
|
February 23, 2007
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide
Nigel Irwin, Paula L McClean, Roslyn S Cassidy, et al.
Metabolites
|
June 21, 2017
Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease
Xiaobei Pan, Christopher T Elliott, Bernadette McGuinness, et al.
European Journal of Endocrinology
|
September 17, 2009
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation
Aine M McKillop, Nicola A Duffy, John R Lindsay, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
February 15, 2007
Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice
Finbarr P M O'Harte, Kerry Hunter, Victor A Gault, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 116) with videos related to
Sort By:
Page
of 12
Journal of Medicinal Chemistry
|
February 3, 2006
GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential
Nigel Irwin, Finbarr P M O'Harte, Victor A Gault, et al.
Biological Chemistry
|
October 21, 2004
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice
Nigel Irwin, Victor A Gault, Brian D Green, et al.
Journal of Medicinal Chemistry
|
February 18, 2005
Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide
Nigel Irwin, Brian D Green, Victor A Gault, et al.
Cell Biology International
|
February 5, 2004
N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression
Hui-Kang Liu, Brian D Green, Victor A Gault, et al.
Biological Chemistry
|
October 7, 2005
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)
Nigel Irwin, Victor A Gault, Brian D Green, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 2, 2006
Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice
Brian D Green, Kerry S Lavery, Nigel Irwin, et al.
Diabetes/Metabolism Research and Reviews
|
February 23, 2007
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide
Nigel Irwin, Paula L McClean, Roslyn S Cassidy, et al.
Metabolites
|
June 21, 2017
Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease
Xiaobei Pan, Christopher T Elliott, Bernadette McGuinness, et al.
European Journal of Endocrinology
|
September 17, 2009
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation
Aine M McKillop, Nicola A Duffy, John R Lindsay, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
February 15, 2007
Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice
Finbarr P M O'Harte, Kerry Hunter, Victor A Gault, et al.
Page
of 12